Empastar 10 mg (Tablet)

Indications

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• Reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Pharmacology

• Sodium glucose co-transporter-2 (SGLT-2) inhibitor
• Reduces renal absorption of glucose
• Leads to increased glucose excretion
• Contributes to reduced hyperglycemia, weight loss, and reduced blood pressure

Dosage & Administration

• Recommended dose of 10 mg once daily
• Can be taken with or without food
• Dose may be increased to 25 mg once daily in patients tolerating it

Interaction

• Co-administration with diuretics increases urine volume
• Increased risk of hypoglycemia when co-administered with insulin or insulin secretagogues
• SGLT2 inhibitors lead to positive urine glucose tests and unreliable 1,5-AG assay measurements for glycemic control

Contraindications

• Not for patients with serious hypersensitivity reaction
• Not for patients with severe renal impairment, end-stage renal disease, or undergoing dialysis

Side Effects

• Common adverse reactions: urinary tract infections and female genital mycotic infections
• Other common side effects: dehydration, hypotension, weakness, dizziness, increased thirstiness

Pregnancy & Lactation

• Potential benefit justifies the potential risk to the fetus for use during pregnancy
• Not recommended during breastfeeding

Precautions & Warnings

• Assessment of renal function recommended prior to initiation
• Not initiated in patients with an eGFR less than 45 ml/min/1.73 m^2
• No dose adjustment needed in patients with eGFR greater than or equal to 45 ml/min/1.73 m^2

Overdose Effects

• Usual supportive measures recommended in the event of an overdose
• Hemodialysis has not been studied for Empastar removal

Therapeutic Class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

• Keep in a cool & dry place (below 30°C)
• Protected from light & moisture
• Keep out of the reach of children

Chemical Structure

• Molecular Formula: C23H27ClO7
• Chemical Structure Image: [Link to Structure Image]

Common Questions about Empastar 10 mg Tablet

• Reduces the reabsorption of glucose from the kidney
• Used to improve glycemic control in adults
• May be unsafe to use during pregnancy
• Probably unsafe to use during breastfeeding
• Should be used cautiously in patients with an underlying kidney disease
• No dose adjustment needed for patients with mild to moderate liver disease
• Quick Tips: Includes usage guidance, precautions, and monitoring advice

Related Brands

• Emaglin 25 mg (Tablet) - dbl-pharmaceuticals-ltd
• Emaglin 10 mg (Tablet) - dbl-pharmaceuticals-ltd
• Empastar 25 mg (Tablet) - goodman-pharmaceuticals-ltd